Oruka Therapeutics (NASDAQ:ORKA) Director Carl Dambkowski Sells 12,583 Shares

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Director Carl Dambkowski sold 12,583 shares of the company’s stock in a transaction dated Friday, June 12th. The shares were sold at an average price of $70.11, for a total transaction of $882,194.13. Following the sale, the director directly owned 38,743 shares of the company’s stock, valued at $2,716,271.73. The trade was a 24.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Carl Dambkowski also recently made the following trade(s):

• On Thursday, June 11th, Carl Dambkowski sold 22,417 shares of Oruka Therapeutics stock. The stock was sold at an average price of $70.13, for a total transaction of $1,572,104.21.
• On Thursday, May 21st, Carl Dambkowski sold 105,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $58.97, for a total value of $6,191,850.00.

Oruka Therapeutics Price Performance

Shares of NASDAQ:ORKA traded up $1.42 during mid-day trading on Friday, reaching $69.89. 781,454 shares of the company traded hands, compared to its average volume of 1,072,342. The company’s 50 day moving average price is $63.01 and its 200-day moving average price is $43.76. The firm has a market cap of $4.22 billion, a PE ratio of -36.03 and a beta of -0.26. Oruka Therapeutics, Inc. has a 52 week low of $10.77 and a 52 week high of $91.00.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.04. On average, research analysts predict that Oruka Therapeutics, Inc. will post -2.06 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on ORKA shares. HC Wainwright reaffirmed a “buy” rating on shares of Oruka Therapeutics in a research note on Wednesday, June 3rd. Wall Street Zen upgraded Oruka Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, March 16th. Stifel Nicolaus upped their target price on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. Wedbush set a $165.00 price target on Oruka Therapeutics in a research report on Monday, April 27th. Finally, BTIG Research reissued a “buy” rating and set a $151.00 price objective on shares of Oruka Therapeutics in a report on Thursday, May 14th. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Oruka Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $131.30.

Institutional Trading of Oruka Therapeutics

Several large investors have recently added to or reduced their stakes in ORKA. Royal Bank of Canada boosted its position in Oruka Therapeutics by 47.2% in the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after buying an additional 365 shares during the last quarter. Los Angeles Capital Management LLC purchased a new position in Oruka Therapeutics during the fourth quarter worth approximately $37,000. PNC Financial Services Group Inc. acquired a new position in Oruka Therapeutics during the third quarter worth $39,000. Caitong International Asset Management Co. Ltd purchased a new stake in Oruka Therapeutics during the 4th quarter worth approximately $67,000. Finally, Russell Investments Group Ltd. purchased a new position in Oruka Therapeutics in the 3rd quarter valued at $43,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.